FDAnews
www.fdanews.com/articles/130564-orbusneich-rsquo-s-bio-engineered-stent-shows-favorable-safety-profile-clinical-outcomes

OrbusNeich’s Bio-Engineered Stent Shows Favorable Safety Profile, Clinical Outcomes

September 24, 2010
OrbusNeich announced that six-month follow-up clinical trial data demonstrate the excellent safety profile and efficacy of the company’s Genous Bio-engineered R stent in combination with a paclitaxel-coated balloon for the treatment of de novo coronary artery disease.
WTHR